Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

ADC + BR improves response rate in diffuse large B-cell lymphoma

Sehn LH et al. EHA Congress, Abstract S802.

Publish date:: June 27, 2018

Key clinical point: An antibody-drug conjugate plus standard therapy led to survival improvement in advanced diffuse large B-cell lymphoma.

Major finding: The complete response rate with polatuzumab vedotin plus bendamustine/rituximab (BR) was 40%, compared with 15% for BR alone.

Study details: Randomized controlled phase 2 trial in 80 patients with relapsed/refractory DLBCL.

Disclosures: The study was funded by Hoffman-La Roche. Dr. Sehn reported ties to Roche/Genentech and others.

Read the article.

Citation:

Sehn LH et al. EHA Congress, Abstract S802.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Aggressive Lymphomas

Study Halted; ‘Hyperprogression’ Seen With Nivolumab for R/R PTCL,

CAR T-Cell Therapy Found Safe, Effective For HIV-Associated Lymphoma,

Bispecific CAR T-cell Therapy Yields Complete Responses in Relapsed/Refractory non-Hodgkin Lymphomas,

5F9 Plus Rituximab Take a Bite Out of Drug-Resistant NHL,

‘Encouraging’ Responses Seen With Durvalumab Plus R-CHOP in DLBCL,

All Specialties